Molecular Cardioprotection: How Pediatric Myosin Inhibition Redefines the Economics of Congenital Heart Care
Dr. Dereck Mush, MD, MBA
What they do
UltraSight develops AI-driven software that provides real-time guidance to non-specialists during cardiac ultrasound scans. The technology guides clinicians to optimal imaging windows, allowing medical staff in emergency rooms and urgent care clinics to acquire diagnostic-grade echocardiograms.
The record
- Vertical
- Cardiovascular
- Sub-segment
- Echocardiography AI
- Product type
- Software as a medical device
- Stage
- Series B
- Headquarters
- Ness Ziona, Israel
- Region
- Middle East & Africa
- Founded
- 2018
- Total funding
- $18M raised
Notable investors: Yozma Group, OurCrowd, AAL, Weizmann Institute of Science.
Also in Cardiovascular
Related on The Signal
Dr. Dereck Mush, MD, MBA
Opportunistic Valvular Screening: How Routine ECG-AI Expands the Structural Heart Pipeline
Dr. Dereck Mush, MD, MBA
Top 25 Cardiologists to Follow on LinkedIn in 2026
Dr. Dereck Mush, MD, MBA
The ECG-to-Echo Pathway: Where Tempus ECG-MR Must Prove Its Value
Dr. Dereck Mush, MD, MBA